Boyd MA; Cooper DA, 2011, 'Antiretroviral agents', in Finch RG; Freenwood D; Whitley RJ; Norrby SR (ed.), Antibiotic and Chemotherapy: anti-infective agents and their use in therapy, edn. 9, Elsevier, London, pp. 472 - 493
Boyd MA; Crowe SM, 2010, 'Indinavir', in Grayson ML; Crowe SM; McCarthy JS; Mills J; Mouton JW; Norrby SR; Paterson DL; Pfaller MA (ed.), Kucers' the use of antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs, edn. 6th, Hodder Arnold, London, pp. 2776 - 2787
Berry M; Boyd MA, 2009, 'Infectious Diseases', in Fulde G (ed.), Emergency Medicine, the Principles of Practice, edn. 5th, Elsevier, Australia, pp. 640 - 664, http://shop.mja.com.au/
Boyd MA; Cooper DA, 2008, 'Implementation of antiretroviral therapy in developing countries.', in Soriano V; Cooper DA (ed.), International HIV/AIDS Updates: Antiretroviral Therapy, edn. Original, Permanyer Publications, Barcelona, pp. 179 - 192
Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', J Virus Erad, vol. 4, pp. 143 - 159, https://www.ncbi.nlm.nih.gov/pubmed/30050676
Stockdale AJ; Saunders MJ; Boyd MA; Bonnett LJ; Johnston V; Wandeler G; Schoffelen AF; Ciaffi L; Stafford K; Collier AC, 2018, 'Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Sah', Clinical Infectious Diseases, vol. 66, pp. 1846 - 1857, http://dx.doi.org/10.1093/cid/cix1108
Yao AH; Moore CL; Lim PL; Molina JM; Madero JS; Kerr S; Mallon PWG; Emery S; Cooper DA; Boyd MA, 2018, 'Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial', Antiviral Therapy, vol. 23, pp. 21 - 32, http://dx.doi.org/10.3851/IMP3171
Mwasakifwa GE; Moore C; Carey D; Amin J; Penteado P; Losso M; Lim PL; Mohapi L; Molina JM; Gazzard B, 2018, 'Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy', AIDS, vol. 32, pp. 357 - 361, http://dx.doi.org/10.1097/QAD.0000000000001688
Boyd MA; Cooper DA, 2018, 'Combination ART: are two drugs as good as three?', The Lancet, vol. 391, pp. 817 - 819, http://dx.doi.org/10.1016/S0140-6736(18)30008-4
Boyd MA; Cooper DA; Gilks CF, 2018, 'Towards a universal second-line fixed-dose combination ART', The Lancet HIV, vol. 5, pp. e3 - e5, http://dx.doi.org/10.1016/S2352-3018(17)30180-7
Petoumenos K; Choi JY; Hoy J; Kiertiburanakul S; Ng OT; Boyd M; Rajasuriar R; Law M, 2017, 'CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy', Antiviral Therapy, vol. 22, pp. 659 - 668, http://dx.doi.org/10.3851/IMP3155
Boyd MA; Mocroft A; Ryom L; Monforte AD; Sabin C; El-Sadr WM; Hatleberg CI; De Wit S; Weber R; Fontas E, 2017, 'Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study', PLoS Medicine, vol. 14, http://dx.doi.org/10.1371/journal.pmed.1002424
Boyd MA, 2017, 'Body composition substudy of the SECOND-LINE study – Author's reply', The Lancet HIV, vol. 4, pp. e240, http://dx.doi.org/10.1016/S2352-3018(17)30093-0
Thit SS; Aung NM; Htet ZW; Boyd MA; Saw HA; Anstey NM; Kyi TT; Cooper DA; Kyi MM; Hanson J, 2017, 'The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: An observational study', BMC Medicine, vol. 15, http://dx.doi.org/10.1186/s12916-017-0888-3
Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2017, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines.', J Virus Erad, vol. 3, pp. 168 - 184, https://www.ncbi.nlm.nih.gov/pubmed/28758027
Boyd MA; Cooper DA, 2017, 'Long-acting injectable ART: next revolution in HIV?', The Lancet, vol. 390, pp. 1468 - 1470, http://dx.doi.org/10.1016/S0140-6736(17)31962-1
Rhee SY; Varghese V; Holmes SP; Van Zyl GU; Steegen K; Boyd MA; Cooper DA; Nsanzimana S; Saravanan S; Charpentier C, 2017, 'Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration', EBioMedicine, vol. 18, pp. 225 - 235, http://dx.doi.org/10.1016/j.ebiom.2017.03.024
Aung NM; Hanson J; Kyi TT; Htet ZW; Cooper DA; Boyd MA; Kyi MM; Saw HA, 2017, 'HIV care in Yangon, Myanmar; successes, challenges and implications for policy', AIDS Research and Therapy, vol. 14, http://dx.doi.org/10.1186/s12981-017-0137-z
Puhr R; Petoumenos K; Youds D; Law MG; Templeton DJ; Ellis D; Bloch M; Agrawal S; Vincent T; Allen D, 2017, 'The impact of changes in HIV management guidelines on time to treatment initiation in Australia', HIV Medicine, vol. 18, pp. 701 - 703, http://dx.doi.org/10.1111/hiv.12504
Lau A; Kong F; Fairley CK; Donovan B; Chen M; Bradshaw C; Boyd M; Amin J; Timms P; Tabrizi S, 2017, 'Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised co', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-016-2125-7
Boyd MA; Amin J; Mallon PWG; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I, 2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients wi', The Lancet HIV, vol. 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8
Boyd MA; Cooper DA, 2016, 'Novel antiretroviral agents and universal access to HIV care', The lancet. HIV, vol. 3, pp. e2 - e3, http://dx.doi.org/10.1016/S2352-3018(15)00244-1
Arts E; Boyd M, 2016, 'Reviewer acknowledgement.', AIDS Res Ther, vol. 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8
Boyd M; Cooper D; Crock EA; Crooks L; Giles ML; Grulich A; Lewin SR; Nolan D; Yarwood T, 2016, 'Sexual transmission of HIV and the law: An Australian medical consensus statement', Medical Journal of Australia, vol. 205, pp. 409 - 412, http://dx.doi.org/10.5694/mja16.00934
Zaunders J; Danta M; Bailey M; Mak G; Marks K; Seddiki N; Xu Y; Templeton DJ; Cooper DA; Boyd MA, 2016, 'CD4+ T follicular helper and IgA+ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals', Frontiers in Immunology, vol. 7, http://dx.doi.org/10.3389/fimmu.2016.00438
Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; Van Wyk J; Teppler H; Kumarasamy N; Molina JM, 2016, 'Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study', AIDS Research and Human Retroviruses, vol. 32, pp. 841 - 850, http://dx.doi.org/10.1089/aid.2015.0331
Achhra AC; Mwasakifwa G; Amin J; Boyd MA, 2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', The Lancet HIV, vol. 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7
Boyd MA; Cooper DA, 2016, 'Tenofovir alafenamide: safer, but questions remain', The Lancet HIV, vol. 3, pp. e148 - e149, http://dx.doi.org/10.1016/S2352-3018(16)00039-4
Alvarez E; Belloso WH; Boyd MA; Inkaya AC; Hsieh E; Kambugu A; Kaminski G; Martinez E; Stellbrink HJ; Walmsley S, 2016, 'Which HIV patients should be screened for osteoporosis: An international perspective', Current Opinion in HIV and AIDS, vol. 11, pp. 268 - 276, http://dx.doi.org/10.1097/COH.0000000000000269
Arts E; Boyd M, 2016, 'Reviewer acknowledgement.', AIDS Res Ther, vol. 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8
Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H, 2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS O', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0140623
Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, vol. 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5
Boyd MA; Cooper DA, 2015, 'The LATTE study: A provocative brew', The Lancet Infectious Diseases, vol. 15, pp. 1116 - 1117, http://dx.doi.org/10.1016/S1473-3099(15)00224-8
Templeton DJ; Wright ST; McManus H; Lawrence C; Russell DB; Law MG; Petoumenos K; Ellis D; Bloch M; Agrawal S, 2015, 'Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)', BMC Infectious Diseases, vol. 15, http://dx.doi.org/10.1186/s12879-015-1051-4
McManus H; Hoy JF; Woolley I; Boyd MA; Kelly MD; Mulhall B; Roth NJ; Petoumenos K; Law MG, 2015, 'Recent trends in early stage response to combination antiretroviral therapy in Australia', Antiviral Therapy, vol. 20, pp. 131 - 139, http://dx.doi.org/10.3851/IMP2774
McManus H; Hoy JF; Woolley I; Boyd MA; Kelly MD; Mulhall B; Roth NJ; Petoumenos K; Law MG, 2015, 'Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia', Antiviral Therapy, vol. 20, pp. 255, http://dx.doi.org/10.3851/IMP2822
Cummins NW; Neuhaus J; Chu H; Neaton J; Wyen C; Rockstroh JK; Skiest DJ; Boyd MA; Khoo S; Rotger M, 2015, 'Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis', EBioMedicine, http://dx.doi.org/10.1016/j.ebiom.2015.05.012
Boyd MA; Donovan B; Prestage G; Chen M; Petoumenos K; Gray R; Guy R; Rogers GB; Bourne C; Klausner JD, 2015, 'Is it time to rethink syphilis control?', Clinical Infectious Diseases, vol. 60, pp. 325 - 326, http://dx.doi.org/10.1093/cid/ciu813
Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H, 2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0118228
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H, 2015, 'Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis', The Lancet HIV, vol. 2, pp. e42 - e51, http://dx.doi.org/10.1016/S2352-3018(14)00061-7
Han N; Wright ST; O'Connor CC; Hoy J; Ponnampalavanar S; Grotowski M; Zhao HX; Kamarulzaman A; Ellis D; Bloch M, 2015, 'HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD)', HIV Medicine, vol. 16, pp. 152 - 160, http://dx.doi.org/10.1111/hiv.12188
Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, http://dx.doi.org/10.1097/QAI.0000000000000288
Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C, 2014, 'Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority', The Lancet, vol. 384, pp. 1942 - 1951, http://dx.doi.org/10.1016/S0140-6736(14)61170-3
Holt SG; Gracey DM; Levy MT; Mudge DW; Irish AB; Walker RG; Baer R; Sevastos J; Abbas R; Boyd MA, 2014, 'A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection', AIDS Research and Therapy, vol. 11, http://dx.doi.org/10.1186/1742-6405-11-35
Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ ritonavir compared with standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, vol. 67, pp. 161 - 168, http://dx.doi.org/10.1097/QAI.0000000000000288
Wright ST; Hoy J; Mulhall B; OʼConnor CC; Petoumenos K; Read T; Smith D; Woolley I; Boyd MA, 2014, 'Determinants of Viremia Copy-Years in People With HIV/AIDS After Initiation of Antiretroviral Therapy', JAIDS Journal of Acquired Immune Deficiency Syndromes, vol. 66, pp. 55 - 64, http://dx.doi.org/10.1097/QAI.0000000000000125
Achhra AC; Boyd MA; Law MG; Matthews GV; Kelleher AD; Cooper DA, 2014, 'Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0099530
Revell A; Wang D; Larder B; Boyd M; Emery S; Gazzard B; Reiss P; van Sighem A; Montaner J; Lane H, 2014, 'A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy', HIV Medicine, http://dx.doi.org/10.1111/hiv.12156
Martin A; Moore CL; Mallon PWG; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA, 2013, 'HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral t', PloS one, vol. 8, http://dx.doi.org/10.1371/journal.pone.0077138
Suzuki K; Marks K; Symonds G; Cooper DA; Kelleher AD; Hattori S; Okada S; Ahlenstiel C; Maeda Y; Ishida T, 2013, 'Promoter targeting shRNA suppresses HIV-1 infection in vivo through transcriptional gene silencing', Molecular Therapy - Nucleic Acids, vol. 2, http://dx.doi.org/10.1038/mtna.2013.64
Achhra AC; Boyd MA, 2013, 'Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: A review of the recent literature', AIDS Research and Therapy, vol. 10, http://dx.doi.org/10.1186/1742-6405-10-33
Boyd M, 2013, 'Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virologic', The Lancet, vol. 381, pp. 2091 - 2099, http://dx.doi.org/10.1016/S0140-6736(13)61164-2
Martin A; Moore C; Mallon PWG; Hoy J; Emery S; Belloso W; Phanuphak P; Ferret S; Cooper DA; Boyd MA, 2013, 'Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy', AIDS, vol. 27, pp. 2403 - 2411, http://dx.doi.org/10.1097/01.aids.0000432534.47217.b4
Boyd MA; Cooper DA, 2013, 'SPRING-2 the future of antiretroviral therapy', The Lancet Infectious Diseases, http://dx.doi.org/10.1016/S1473-3099(13)70194-4
Wright ST; Petoumenos K; Boyd M; Carr A; Downing S; O'Connor CC; Grotowski M; Law MG, 2013, 'Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience', HIV Medicine, vol. 14, pp. 208 - 216, http://dx.doi.org/10.1111/j.1468-1293.2012.01053.x
Jansson J; Wilson DP; Carr A; Petoumenos K; Boyd MA, 2013, 'Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV', AIDS, vol. 27, pp. 1245 - 1251, http://dx.doi.org/10.1097/QAD.0b013e32835e163d
Boyd MA; Donovan B, 2013, 'Antiretroviral therapy: dolutegravir sets SAIL(ING)', The Lancet, http://dx.doi.org/10.1016/S0140-6736(13)61456-7
Schneider K; Nwizu C; Kaplan R; Anderson J; Wilson DP; Emery S; Cooper DA; Boyd MA, 2013, 'The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0054435
Wright S; Boyd MA; Yunihastuti E; Law M; Sirisanthana T; Hoy J; Pujari S; Lee MP; Petoumenos K, 2013, 'Rates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Region', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0064902
Byakwaga H; Petoumenos K; Ananworanich J; Zhang F; Boyd MA; Sirisanthana T; Li PCK; Lee C; Mean CV; Saphonn V, 2013, 'Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observationa', Journal of the International Association of Providers of AIDS Care, vol. 12, pp. 270 - 277, http://dx.doi.org/10.1177/1545109712469684
Jansson J; Wilson D; Carr A; Petoumenos K; Boyd M, 2012, 'Currently available medications may not be sufficient for lifelong treatment of HIV', JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 15, pp. 4 - 4, http://dx.doi.org/10.7448/IAS.15.6.18077
Boyd M, 2012, 'Dolutegravir-a promising antiretroviral in development', The Lancet Infectious Diseases, vol. 12, pp. 90 - 91, http://dx.doi.org/10.1016/S1473-3099(11)70291-2
Boyd M; Mohapi L, 2012, 'Stretching delivery of HIV health services', The Lancet, vol. 380, pp. 865 - 867, http://dx.doi.org/10.1016/S0140-6736(12)60952-0
Avihingsanon A; Van Der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K, 2012, 'Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study', AIDS Research and Human Retroviruses, vol. 28, pp. 1170 - 1176, http://dx.doi.org/10.1089/aid.2011.0247
McManus H; O'Connor CC; Boyd M; Broom J; Russell D; Watson K; Roth N; Read PJ; Petoumenos K; Law MG, 2012, 'Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0048839
Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', Journal of Acquired Immune Deficiency Syndromes, vol. 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e
Boyd MA; Cooper DA, 2012, 'Optimisation of HIV care and service delivery: Doing more with less', The Lancet, vol. 380, pp. 1860 - 1866, http://dx.doi.org/10.1016/S0140-6736(12)61154-4
Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; Allworth A; Anderson J; Baker D; Bloch M, 2012, 'Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 7, http://dx.doi.org/10.1371/journal.pone.0038377
Wilson DP; Grulich AE; Boyd M, 2011, 'Overly optimistic forecasts for the impact of treatment of hiv prevention for men who have sex with men', Clinical Infectious Diseases, vol. 53, pp. 611 - 612, http://dx.doi.org/10.1093/cid/cir477
Revell AD; Wang D; Boyd MA; Emery S; Pozniak AL; De Wolf F; Harrigan R; Montaner JSG; Lane C; Larder BA, 2011, 'The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool', AIDS, vol. 25, pp. 1855 - 1863, http://dx.doi.org/10.1097/QAD.0b013e328349a9c2
Byakwaga H; Kelly M; Purcell DFJ; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA, 2011, 'Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 + T-cell response: A randomized controlle', Journal of Infectious Diseases, vol. 204, pp. 1532 - 1540, http://dx.doi.org/10.1093/infdis/jir559
Boyd MA; Nwizu CA, 2010, 'Operational research in HIV priority areas: the African way.', Lancet, vol. 376, pp. 4 - 6, http://dx.doi.org/10.1016/S0140-6736(10)60972-5
Boyd MA; Hill AM, 2010, 'Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.', Pharmacoeconomics, vol. 28 Suppl 1, pp. 17 - 34, http://dx.doi.org/10.2165/11587420-000000000-00000
Carey D; Amin J; Boyd M; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials', Journal of Antimicrobial Chemotherapy, vol. 65, pp. 1878 - 1888, http://dx.doi.org/10.1093/jac/dkq231
Boyd MA, 2010, 'Current and future management of treatment failure in low- and middle-income countries', Current Opinion in HIV and AIDS, vol. 5, pp. 83 - 89, http://dx.doi.org/10.1097/COH.0b013e328333b8c0
Boyd MA; Hill AM, 2010, 'Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era', PharmacoEconomics, vol. 28, pp. 17 - 34, http://dx.doi.org/10.2165/11587420-000000000-00000
Zhou J; Li PCK; Kumarasamy N; Boyd M; Chen YMA; Sirisanthana T; Sungkanuparph S; Oka S; Tau G; Phanuphak P, 2010, 'Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD)', HIV Medicine, vol. 11, pp. 31 - 39, http://dx.doi.org/10.1111/j.1468-1293.2009.00738.x
Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current Opinion in HIV and AIDS, vol. 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.0b013e328329fc8d
Boyd M; Emery S; Cooper DA, 2009, 'Antiretroviral roll-out: the problem of second-line therapy', The Lancet, vol. 374, pp. 185 - 186, http://dx.doi.org/10.1016/S0140-6736(09)61313-1
Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA, 2009, 'Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.', AIDS research and human retroviruses, vol. 25, pp. 756 - 776
McIntyre GJ; Yu YH; Tran A; Jaramillo AB; Arndt AJ; Millington ML; Boyd MP; Elliott FA; Shen SW; Murray JM, 2009, 'Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success', Virology Journal, vol. 6, http://dx.doi.org/10.1186/1743-422X-6-184
Byakwaga H; Zhou J; Petoumenos K; Law MG; Boyd MA; Emery S; Cooper DA; Mallon PW, 2009, 'Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy', HIV Medicine, vol. 10, pp. 143 - 151, http://dx.doi.org/10.1111/j.1468-1293.2008.00663.x
Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current opinion in HIV & AIDS, vol. 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.013e328329fc8d
Boyd M; Pett S, 2008, 'Experimental and clinical pharmacology - HIV fusion inhibitors: a review', AUSTRALIAN PRESCRIBER, vol. 31, pp. 66 - 69, http://dx.doi.org/10.18773/austprescr.2008.040
Boyd M; Byakwaga H, 2008, 'Considering the benefits of disease-specific interventions on overall public health', The Lancet Infectious Diseases, vol. 8, pp. 278, http://dx.doi.org/10.1016/S1473-3099(08)70080-X
Colebunders R; French M; Oelrichs R; Boyd M, 2008, 'Editorial introductions', Current Opinion in HIV and AIDS, vol. 3, http://dx.doi.org/10.1097/COH.0b013e32830890a4
Oelrichs R; Boyd M, 2008, 'Evidence and policy in the globalized response to AIDS', Current Opinion in HIV and AIDS, vol. 3, pp. 477 - 480, http://dx.doi.org/10.1097/COH.0b013e328303ba0b
Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A, 2008, 'A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)', Antiviral Therapy, vol. 13, pp. 449 - 453
Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A, 2007, 'A randomized study to evaluate injection site reactions (ISR) using three different mechanisms for delivery of enfuvirtide (ENF): a 27-gauge needle, a 31-gauge needle and a needle-free device', ANTIVIRAL THERAPY, vol. 12, pp. L57 - L57, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249773400105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Boyd M, 2007, 'Indinavir: The forgotten HIV-protease inhibitor. Does it still have a role?', Expert Opinion on Pharmacotherapy, vol. 8, pp. 957 - 964, http://dx.doi.org/10.1517/14656566.8.7.957
Cooper D; Cahn P; Lewin S; Kaldor J; McClure C; Kort R; Boyd M, 2007, 'The Sydney Declaration: a call to scale up research', Lancet, vol. 370, pp. 7 - 8, http://dx.doi.org/10.1016/S0140-6736(07)61024-1
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG, 2007, 'Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment', HIV Medicine, vol. 8, pp. 46 - 54, http://dx.doi.org/10.1111/j.1468-1293.2007.00427.x
Kerr SJ; Duncombe C; Avihingsanon A; Ananworanich J; Boyd M; Sopa B; Chuenyam T; Cooper DA; Lange JMA; Phanuphak P, 2007, 'Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens', Journal of the International Association of Physicians in AIDS Care, vol. 6, pp. 36 - 46, http://dx.doi.org/10.1177/1545109706295946
Boyd MA; Cooper DA, 2007, 'Second-line combination antiretroviral therapy in resource-limited settings: Facing the challenges through clinical research', AIDS, vol. 21, http://dx.doi.org/10.1097/01.aids.0000279707.01557.b2
Autar RS; Boyd MA; Wit FWMN; Ruxrungtham K; Sankote J; Lange JMA; Cooper DA; Phanuphak P; Burger DM; Reiss P, 2007, 'Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen', Antiviral Therapy, vol. 12, pp. 1265 - 1271
Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EAM; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M, 2006, 'Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)', Antiviral Therapy, vol. 11, pp. 223 - 232
Boyd MA; Burger DM; Phanuphak P; Cooper DA, 2006, 'Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis [4]', AIDS, vol. 20, pp. 1083 - 1085, http://dx.doi.org/10.1097/01.aids.0000222090.52035.b2
Boyd MA; Srasuebkul P; Ruxrungtham K; Mackenzie PI; Uchaipichat V; Stek M; Lange JMA; Phanuphak P; Cooper DA; Udomuksorn W, 2006, 'Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir', Pharmacogenetics and Genomics, vol. 16, pp. 321 - 329, http://dx.doi.org/10.1097/01.fpc.0000197465.14340.d4
Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JMA; Phanuphak P; Cooper DA; Burger DM, 2006, 'The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity', Journal of Antimicrobial Chemotherapy, vol. 57, pp. 1161 - 1167, http://dx.doi.org/10.1093/jac/dkl112
Boyd MA; Carr A; Ruxrungtham K; Srasuebkul P; Bien D; Law M; Wangsuphachart S; Krisanachinda A; Lerdlum S; Lange JMA, 2006, 'Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz', Journal of Infectious Diseases, vol. 194, pp. 642 - 650, http://dx.doi.org/10.1086/505709
Boyd MA; Dixit NM; Siangphoe U; Buss NE; Salgo MP; Lange JMA; Phanuphak P; Cooper DA; Perelson AS; Ruxrungtham K, 2006, 'Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012)', Journal of Infectious Diseases, vol. 194, pp. 1319 - 1322, http://dx.doi.org/10.1086/508291
Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J, 2005, 'Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients', Antiviral Therapy, vol. 10, pp. 301 - 307
Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JMA; Cooper DA; Phanuphak P, 2005, 'Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009', HIV Medicine, vol. 6, pp. 410 - 420, http://dx.doi.org/10.1111/j.1468-1293.2005.00327.x
Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Fanning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray J, 2005, 'Long-term survival and concomitant gene expression of ribozyme-transduced CD
Ananworanich J; Cheunyam T; Teeratakulpisarn S; Boyd MA; Ruxrungtham K; Lange PJ; Cooper PD; Phanuphak PP, 2004, 'Creation of a drug fund for post-clinical trial access to antiretrovirals', Lancet, vol. 364, pp. 101 - 102, http://dx.doi.org/10.1016/S0140-6736(04)16596-3
Law WP; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JMA; Phanuphak P; Cooper DA; Dore GJ, 2004, 'Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort', AIDS, vol. 18, pp. 1169 - 1177, http://dx.doi.org/10.1097/00002030-200405210-00010
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH, 2004, 'Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients', Journal of Clinical Pharmacology, vol. 44, pp. 793 - 802, http://dx.doi.org/10.1177/0091270004266489
Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J, 2003, 'Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients', Journal of Antimicrobial Chemotherapy, vol. 51, pp. 1231 - 1238, http://dx.doi.org/10.1093/jac/dkg198
Boyd MA; Aarnoutse RE; Ruxrungtham K; Stek M; Van Heeswijk RPG; Lange JMA; Cooper DA; Phanuphak P; Burger DM, 2003, 'Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects', Journal of Acquired Immune Deficiency Syndromes, vol. 34, pp. 134 - 139, http://dx.doi.org/10.1097/00126334-200310010-00003
Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JMA; Phanuphak P; Cooper DA, 2003, 'Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001', AIDS, vol. 17, pp. 2191 - 2199, http://dx.doi.org/10.1097/00002030-200310170-00007
Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH, 2003, 'Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide', Journal of Clinical Pharmacology, vol. 43, pp. 1382 - 1391, http://dx.doi.org/10.1177/0091270003259220
Holt SG; Gracey DM; Mudge DW; Irish AB; Sevastos J; Walker RG; Baer RA; Levy MT; Boyd MA, 2014, 'RENAL FUNCTION TESTING IN PATIENTS ON TENOFOVIR ANTIVIRAL THERAPY', in NEPHROLOGY, WILEY-BLACKWELL, pp. 72 - 72, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339715700206&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Achhra AC; Boyd M; Law MG; Matthews G; Kelleher AD; Cooper DA, 2013, 'Sequencing antiretroviral therapy to maximize patient safety: could we move away from ritonavir, abacavir, tenofovir and efavirenz (RATE) - agents that concern prescribers and patients? A feasibility', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Brussels, BELGIUM, pp. A51 - A51, presented at 15th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Brussels, BELGIUM, 15 - 17 October 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335230200056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Chadwick M; Boyd MA; Cathers B, 1997, 'A water quality modelling tutorial using SIMULINK', in MODSIM 1997: International Congress on Modelling and Simulation, MODSIM 1997: International Congress on Modelling and Simulation, University of Tasmania, Hobart, presented at MODSIM 1997: International Congress on Modelling and Simulation, University of Tasmania, Hobart, 08 - 11 December 1997
Boyd MA; Cathers B; Chadwick M; Craig E, 1996, 'Developing a set of teaching exercises in ennvironmental engineering modelling', in 8th Australasian Association for Engineering Education Conference and Convention, 8th Australasian Association for Engineering Education Conference and Convention, University of New South Wales, presented at 8th Australasian Association for Engineering Education Conference and Convention, University of New South Wales, 15 - 18 December 1996